Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Outpatient Oncology Infusion Market Size & Share 2026-2035
Report ID: GMI5268
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Outpatient Oncology Infusion Market
Get a free sample of this reportWhat are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.

Outpatient Oncology Infusion Market Size
The outpatient oncology infusion market was valued at USD 128.7 billion in 2025, is projected to reach USD 141.6 billion in 2026, and is expected to grow at approximately 9.0% CAGR (2026–2035) to USD 308.0 billion by 2035. The market covers intravenously administered oncology therapeutics delivered through ambulatory infusion centers, physician-office infusion suites, cancer-center outpatient clinics, and hospital outpatient departments.
Outpatient Oncology Infusion Market Key Takeaways
Market Leader: Merck & Co. led with over 19% market share in 2025.
Leading Players: Top 5 players in this market include Merck & Co., Roche/Genentech, Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, which collectively held a market share of 63% in 2025.
The outpatient oncology infusion market is being reshaped by a treatment-mix shift toward complex biologics, including checkpoint inhibitors and antibody-drug conjugates (ADCs), alongside the migration of appropriate cancer care from inpatient settings into lower-acuity outpatient sites. This transition increases both the clinical importance of infusion capacity and the operational value of scheduling, pharmacy coordination, and reimbursement management.
On a supply-side, manufacturer net revenue basis, the market stood at USD 96.8 billion in 2025. This complementary perspective isolates net ex-factory drug revenue sold into the outpatient channel, while the primary provider-billed measure also reflects administration and ancillary service economics.
GMI Analyst View
Based on our supply-channel consultations with oncology manufacturer and payer contacts, the outpatient oncology infusion market on a manufacturer net revenue basis is projected to reach USD 230.1 billion by 2035, reflecting the scale of manufacturer value capture from an outpatient channel that continues to absorb a growing share of all oncology drug volumes as biosimilar pricing recalibrates the reference biologic mix and novel agents expand the overall addressable infusion pool.
Outpatient Oncology Infusion Market Trends, Growth Drivers & GMI Forecast Outlook
Outpatient infusion demand is expanding through a combination of rising cancer incidence, increasingly reimbursed biologic treatment protocols, and regulatory approvals that broaden the infusion-eligible population. Forecast performance will depend on whether capacity expansion and payment structures keep pace with higher-acuity regimens and a more complex drug mix.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Cancer incidence creates a durable volume foundation because lung, breast, colorectal, hematologic, and gynecologic malignancies increasingly rely on infused combination regimens across multiple treatment lines. Earlier diagnosis and wider treatment access can add demand not only through new patient starts, but also through longer care pathways that require repeat infusions, monitoring, and supportive therapy. The projected global cancer burden is expected to continue rising as populations age and diagnostic access broadens [1]IARC / American Cancer Society. "Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries." pmc.ncbi.nlm.nih.gov.
Government reimbursement is particularly consequential where outpatient providers must purchase high-cost drugs before administration. Medicare Part B's drug payment structure, which covers acquisition costs for physician-administered oncology agents in outpatient settings, creates durable provider incentives for ambulatory infusion capacity investment [2]MedPAC. "July 2025 Data Book, Section 10: Prescription Drugs." medpac.gov. The resulting infrastructure economics favor sites able to combine pharmacy controls, payer authorization capabilities, and predictable chair utilization.
New biologic approvals raise demand intensity as well as patient eligibility. ADCs and checkpoint inhibitors are commonly embedded in protocols that require specialized preparation, administration surveillance, and toxicity management. FDA approval activity across new targets and tumor settings therefore expands the addressable infusion pool while increasing the value placed on clinically sophisticated outpatient delivery models [3]U.S. Food and Drug Administration. "Oncology (Cancer)/Hematologic Malignancies Approval Notifications." fda.gov.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Drug shortages affect infusion operations through more than missed drug purchases. When injectable oncology products become constrained, providers must redesign protocols, sequence patients differently, locate substitute therapies, and absorb greater pharmacy and nursing workload. Research on oncology shortages identifies manufacturing quality problems, concentrated supply chains, constrained inventories, and weak generic-production incentives as recurring vulnerabilities [4]Cooper et al. "Key Drivers and Mitigation Strategies of Oncology Drug Shortages." pmc.ncbi.nlm.nih.gov. These disruptions can reduce throughput even when clinical teams preserve continuity of care through substitutions.
Biosimilar adoption produces a different form of pressure. Lower-priced alternatives can improve access and maintain treatment volumes, yet they reduce reference-product revenue capture and reshape manufacturer economics. This distinction matters because provider-billed market expansion can continue even when the supply-side value of established antibody franchises is compressed. Reported biosimilar uptake in core oncology antibody categories indicates that this effect is becoming structural rather than temporary [5]AJMC. "Samsung Bioepis Reports 2024 Biosimilar Market Growth Trends." ajmc.com.
Payment design also influences where treatment is delivered and which operators can invest in new capacity. Differences across hospital outpatient departments and physician-office sites can alter referral patterns, while prior authorization and evolving drug-pricing policy add administrative and financial uncertainty. Medicare's Part B payment framework remains central to this site-of-care calculus [6]MedPAC. "Part B Drugs Payment Systems." medpac.gov.
GMI Analyst View
We see a market in which clinical demand and economic value do not move in perfect alignment. Novel infusible therapies are raising treatment complexity and supporting outpatient utilization, while biosimilar competition and reimbursement reform increasingly separate provider revenue opportunities from the net value captured by manufacturers. Operators with disciplined drug procurement and authorization capabilities should be better positioned than capacity-only providers.
Outpatient Oncology Infusion Market Segment Analysis
By Therapy Type
Checkpoint Inhibitors
Checkpoint inhibitors generated USD 30.9 billion in 2025 and are projected to reach USD 75.0 billion by 2035. Their position reflects broad use across solid tumors and continued movement into earlier disease settings. The outpatient oncology infusion market benefits from the category's recurring administration schedules and expanding combination use. As treatment shifts from later-line to perioperative and first-line settings, providers must manage larger patient cohorts over longer therapy journeys, reinforcing demand for dependable infusion-chair capacity.
Monoclonal antibodies (non-checkpoint) accounted for 22.1% of the market in 2025 and are forecast to reach USD 60.0 billion by 2035. The segment includes established HER2-, CD20-, and VEGF-targeted therapies used across high-volume oncology protocols. Biosimilar competition is changing the segment's commercial mix without eliminating its operational importance. Infusion providers retain substantial demand for these therapies, but market participants increasingly compete on formulary access, sourcing reliability, administration efficiency, and their ability to integrate lower-cost alternatives into established care pathways.
Cytotoxic Chemotherapy
Cytotoxic chemotherapy represented USD 23.2 billion in 2025 and is expected to account for 13.0% of the market by 2035. It remains a major therapeutic backbone despite a declining relative revenue position. The category remains integral to combination regimens in lung, colorectal, breast, gynecologic, and other cancers. Its strategic role is shifting from primary revenue engine to essential companion therapy, with demand influenced by generic supply reliability, protocol standardization, and the pace at which biologics displace or augment conventional regimens.
Supportive Care Infusions
Supportive care infusions are projected to reach USD 37.0 billion by 2035 and are expected to grow at approximately 9.5% CAGR (2026–2035). The category encompasses therapies that help patients remain on intensive oncology treatment programs. As more patients receive complex biologic and combination therapies in outpatient settings, supportive care becomes increasingly tied to overall treatment-course intensity. Providers that coordinate antiemetics, bone-modifying agents, and hematologic support within the same visit pathway can improve chair utilization and reduce disruptions across the broader infusion schedule.
Targeted Therapy (Non-Antibody Infusibles)
Targeted therapy (non-antibody infusibles) accounted for 10.0% of the market in 2025 and is projected to reach USD 32.0 billion by 2035. The segment includes infused targeted products used in hematologic malignancies and solid tumors. Demand is supported by the growing use of multidrug protocols that combine targeted agents with immunotherapy or chemotherapy. The category's outpatient relevance depends on treatment sequencing, clinical monitoring requirements, and a provider's ability to manage diverse protocols without compromising pharmacy and nursing workflow.
Antibody-Drug Conjugates (ADCs)
ADCs generated USD 11.6 billion in 2025 and are expected to advance at approximately 14.5% CAGR (2026–2035). This is the strongest growth trajectory among therapy types. ADCs elevate outpatient infusion intensity because they are high-acuity biologics requiring careful dosing, monitoring, and adverse-event management. Their expansion across breast, lung, gynecologic, and hematologic malignancies supports a mix upgrade for providers, especially those able to accommodate longer appointments and more complex clinical oversight.
Hormonal Therapy (Injectable/Infused)
Hormonal therapy is projected to reach USD 19.0 billion by 2035 and accounted for 6.0% of the market in 2025. The segment includes recurring injectable and infused regimens used particularly in prostate and breast cancer management. Its commercial profile is comparatively stable because recurring administration schedules create predictable encounters. Physician-office sites are especially important to this category, where convenience, ongoing patient follow-up, and reliable reimbursement can matter as much as novel-product adoption.
By Tumor Type
Hematologic Cancers
Hematologic cancers generated USD 28.4 billion in 2025 and are projected to grow at approximately 8.5% CAGR (2026–2035). The segment is supported by infused antibodies, targeted therapies, and combination regimens across multiple myeloma, lymphoma, and leukemia care. These diseases often involve longitudinal treatment sequences, making continuity of outpatient pharmacy and infusion operations critical. The category rewards providers that can manage regimen complexity, repeat visits, supportive care, and transitions between active therapy and maintenance.
Lung Cancer (NSCLC/SCLC)
Lung cancer accounted for 19.0% of the market in 2025 and is projected to reach USD 65.0 billion by 2035. Checkpoint inhibitor-based treatment has made this tumor type a central source of outpatient infusion demand. Growth reflects the extension of immunotherapy across earlier and metastatic disease, alongside the addition of biomarker-defined ADC opportunities. Treatment pathways increasingly require coordination among diagnostics, medical oncology, infusion operations, and payer authorization teams, making operational integration a competitive differentiator.
Breast Cancer
Breast cancer generated USD 21.9 billion in 2025 and is expected to grow at approximately 10.0% CAGR (2026–2035). This performance is tied to expanding use of HER2-directed treatment, immunotherapy, and ADCs. The shift toward biomarker-defined treatment creates a more differentiated infusion mix. Providers must align testing turnaround, physician decision-making, drug procurement, and patient scheduling to capture the full value of increasingly personalized regimens.
Colorectal Cancer
Colorectal cancer accounted for 9.0% of the market in 2025 and is projected to reach USD 25.0 billion by 2035. Chemotherapy backbones, targeted antibodies, and selected immunotherapy use continue to define the segment. The category remains commercially important because of its high treatment volume and frequent combination protocols. However, its market trajectory is moderated by the continuing role of lower-cost cytotoxics and the narrower population eligible for biomarker-driven immunotherapy.
Prostate Cancer
Prostate cancer accounted for 7.0% of the market in 2025 and is projected to reach USD 22.0 billion by 2035. Long-cycle hormonal injection programs and the use of infused therapies in advanced disease support recurring outpatient activity. The segment's demand profile is shaped by chronic disease management rather than short-duration acute intervention. Providers can benefit from predictable follow-up patterns, although treatment selection depends heavily on disease stage, payer coverage, and care coordination across urology and oncology.
Gynecologic Cancers
Gynecologic cancers accounted for 6.0% of the market in 2025 and are projected to reach USD 18.0 billion by 2035. The segment draws on platinum-based combinations, biologics, checkpoint inhibitors, and ADCs across ovarian, endometrial, and cervical cancers. Novel-agent adoption is raising the importance of specialist outpatient programs able to manage toxicity surveillance and complex sequencing. As treatment options broaden, referral networks and access to molecular testing will increasingly influence where infusion demand is concentrated.
Melanoma
Melanoma accounted for 5.0% of the market in 2025 and is projected to reach USD 15.0 billion by 2035. The segment remains closely tied to outpatient checkpoint inhibitor administration. Immunotherapy penetration is already substantial, so growth will depend more on use across adjuvant and neoadjuvant settings than on first-time adoption alone. This creates steady demand for clinically experienced infusion services rather than an unlimited expansion in treatment intensity.
Head & Neck Cancer
Head & neck cancer is projected to reach USD 15.0 billion by 2035 and is expected to grow at approximately 8.5% CAGR (2026–2035). Checkpoint inhibitors and antibody-based regimens are central to the segment's outpatient treatment model. Care delivery is operationally demanding because patients often require close nutritional, symptom-management, and multidisciplinary support alongside systemic therapy. Infusion providers with integrated supportive-care capabilities may be better positioned to manage this patient population.
GI Cancers
GI cancers accounted for 5.0% of the market in 2025 and are expected to grow at approximately 7.5% CAGR (2026–2035). The category includes gastric, gastroesophageal junction, pancreatic, hepatocellular, biliary tract, and related malignancies treated with infused regimens. Growth is moderated by clinically heterogeneous disease populations and variable treatment duration. Nevertheless, targeted antibodies and immunotherapy are gradually increasing regimen complexity, creating opportunities for specialized outpatient centers that can coordinate care across multiple gastrointestinal oncology pathways.
Other Tumor Types
Other tumor types accounted for 5.0% of the market in 2025 and are projected to represent 3.6% by 2035. This group includes lower-incidence malignancies in which infused checkpoint inhibitors and targeted therapies are gaining relevance. The declining relative share does not indicate reduced clinical importance. Rather, it reflects faster expansion in major tumor categories where large patient populations and new biologic approvals are concentrating a greater portion of outpatient infusion demand.
GMI Analyst View
We believe the therapy mix is becoming more valuable and more operationally demanding at the same time. ADCs, checkpoint inhibitors, and biomarker-directed protocols are increasing the clinical sophistication required at outpatient sites, while established chemotherapy and antibody programs continue to anchor visit volume. The winners will be providers that can scale complex regimens without compromising patient flow or drug-access discipline.
Outpatient Oncology Infusion Market Regional Analysis
North America Outpatient Oncology Infusion Market Analysis
North America generated USD 59.2 billion in 2025 and is projected to reach USD 127.0 billion by 2035. The outpatient oncology infusion market in the region is supported by mature ambulatory infrastructure, broad payer coverage for high-cost biologics, and early uptake of new oncology therapies. The region's established oncology networks provide a strong base for complex infusion delivery. Its future growth will depend on reimbursement design, site-of-care migration, biosimilar adoption, and the ability of providers to absorb higher-acuity regimens while controlling drug and labor costs.
U.S.
The U.S. generated USD 57.0 billion in 2025 and is projected to reach USD 122.0 billion by 2035. Its scale reflects Medicare Part B coverage, a dense base of physician-office infusion suites and hospital outpatient departments, and early use of checkpoint inhibitors and ADCs. The U.S. remains the principal commercial market for infused oncology therapies, but payment reform and site-neutrality pressures may influence which facilities capture future demand. Antineoplastics are the largest therapeutic class in Medicare Part B spending, underscoring the channel's importance to outpatient care economics [2]MedPAC. "July 2025 Data Book, Section 10: Prescription Drugs." medpac.gov.
Canada
Canada generated USD 2.2 billion in 2025 and is expected to grow at approximately 8.5% CAGR (2026–2035). Public reimbursement negotiations and ambulatory cancer-care investment support the country's outpatient infusion model. Growth will depend on the timing of access decisions for novel therapies and provincial capacity planning. The market favors systems that can extend treatment access while maintaining centralized purchasing discipline and equitable cancer-care delivery.
Europe Outpatient Oncology Infusion Market Analysis
Europe accounted for 23.0% of the market in 2025 and is projected to reach USD 66.5 billion by 2035. The outpatient oncology infusion market is shaped by national health technology assessment processes, broad biosimilar adoption, and a large aging population. Regional demand is supported by widespread outpatient cancer infrastructure, although market access timing differs significantly by country. These differences create uneven uptake for novel biologics and favor manufacturers and providers able to navigate country-specific pricing, reimbursement, and treatment-guideline requirements.
Germany
Germany generated USD 7.0 billion in 2025 and is projected to reach USD 15.0 billion by 2035. Its early-access framework supports rapid use of newly authorized oncology therapies. Germany's reimbursement environment positions it as an important European launch market for novel infusibles. Providers benefit from early treatment access, although subsequent benefit assessment and pricing processes remain important to the durability of adoption.
UK
The UK accounted for 3.9% of the market in 2025 and is projected to reach USD 11.5 billion by 2035. National Health Service delivery and technology appraisals shape access to infused oncology products. Cancer Alliances and specialized outpatient services support coordinated treatment delivery, but adoption remains tied to appraisal outcomes and commissioning priorities. The market therefore combines substantial clinical demand with tightly managed access conditions.
France
France generated USD 5.0 billion in 2025 and is expected to grow at approximately 8.2% CAGR (2026–2035). Its hospital outpatient and private cancer-clinic network provides a broad treatment base. Early-access mechanisms can speed the availability of selected oncology therapies before permanent reimbursement decisions are completed. This supports uptake of innovative infusibles while maintaining a structured national approach to cost control.
Italy
Italy accounted for 3.1% of the market in 2025 and is projected to reach USD 9.0 billion by 2035. AIFA reimbursement decisions and specialized cancer centers support outpatient treatment expansion. The country's managed-entry approach can moderate adoption speed, yet it also creates a framework for disciplined use of high-cost medicines. Investment in integrated oncology centers should remain central to capacity development.
Spain
Spain generated USD 3.0 billion in 2025 and is projected to account for 2.1% of the market by 2035. Centralized purchasing and biosimilar-oriented prescribing shape the country's infusion economics. The market prioritizes treatment access and cost efficiency, creating demand for providers and suppliers that can deliver dependable therapy at controlled acquisition costs. Biosimilar use may preserve encounter volumes while limiting revenue intensity for established brands.
Netherlands
The Netherlands generated USD 2.0 billion in 2025 and is projected to reach USD 4.5 billion by 2035. Academic medical centers serve as important outpatient oncology infusion hubs. Structured reimbursement and managed-entry practices favor concentrated, evidence-led deployment of novel therapies. This environment supports efficient delivery but can limit the speed at which new products diffuse beyond specialized centers.
Asia Pacific Outpatient Oncology Infusion Market Analysis
Asia Pacific generated USD 29.6 billion in 2025 and is expected to grow at approximately 11.5% CAGR (2026–2035). The outpatient oncology infusion market is the fastest-growing regional market, driven by infrastructure buildout, rising cancer burden, and wider reimbursement access. Growth is being led by the expansion of cancer centers, broader insurance coverage, and increasing use of both locally developed and multinational biologics. Market conditions vary widely, but the region's trajectory favors participants that can balance pricing discipline with broadening access outside major metropolitan centers.
China
China generated USD 13.0 billion in 2025 and is projected to reach USD 38.0 billion by 2035. National reimbursement inclusion and expanding hospital capacity are broadening access to infused oncology treatment. Domestic checkpoint inhibitor and ADC development strengthens China's competitive position, while public reimbursement negotiations are increasing the importance of volume-based commercial strategies. Tiered hospital expansion will be central to extending outpatient access beyond leading urban centers.
Japan
Japan accounted for 7.0% of the market in 2025 and is projected to reach USD 22.0 billion by 2035. Universal health insurance and a rapid approval cadence support adoption of infused oncology therapies. Japan combines established cancer-treatment infrastructure with strong domestic innovation in ADCs. The market's high clinical standards and standardized reimbursement framework support rapid incorporation of approved therapies into specialist outpatient practice.
India
India is projected to reach USD 7.5 billion by 2035 and is expected to grow at approximately 14.5% CAGR (2026–2035). Rising cancer incidence, private hospital investment, and improving insurance coverage underpin this expansion. Demand will be concentrated in major urban centers initially, but public programs and expanded private coverage can broaden access over time. Affordability remains a defining constraint, increasing the strategic importance of biosimilars, localized supply, and efficient care models.
South Korea
South Korea accounted for 1.6% of the market in 2025 and is projected to reach USD 6.0 billion by 2035. Centralized reimbursement and a strong biosimilar ecosystem support outpatient oncology delivery. The market benefits from sophisticated hospital infrastructure and efficient access to lower-cost biologics. Future growth will depend on the pace at which reimbursement expands for newer immunotherapy and ADC indications.
Australia
Australia generated USD 2.0 billion in 2025 and is projected to reach USD 5.5 billion by 2035. Public and private cancer-care networks provide a well-developed base for outpatient infusion. Technology assessment and formulary decisions remain central to the pace of novel-agent adoption. Strong clinical-trial activity and specialist cancer centers nevertheless support early use of advanced oncology regimens relative to market size.
Latin America Outpatient Oncology Infusion Market Analysis
Latin America accounted for 5.0% of the market in 2025 and is projected to reach USD 16.0 billion by 2035. The outpatient oncology infusion market is expanding as public coverage, private cancer-care investment, and oncology capacity improve. The region has significant unmet need but faces uneven reimbursement and purchasing power across countries. Growth will be strongest where public access programs, private insurer coverage, and specialized outpatient facilities develop in parallel.
Brazil
Brazil generated USD 3.0 billion in 2025 and is projected to reach USD 7.5 billion by 2035. Its public health system and sizable private payer market create a dual-channel opportunity for outpatient oncology infusion. Large private oncology networks are helping to establish integrated ambulatory treatment models, while public-sector access remains dependent on health technology assessment and funding priorities. The market's size makes Brazil the region's central commercial and operational reference point.
Mexico
Mexico accounted for 1.4% of the market in 2025 and is projected to reach USD 4.5 billion by 2035. Public oncology expansion and private hospital networks are increasing the availability of infusion services. Treatment access remains segmented between publicly funded basic care and commercially insured patients receiving newer biologics. Capacity development in major cities will remain important, but reimbursement continuity will determine the breadth of market expansion.
Argentina
Argentina generated USD 0.6 billion in 2025 and is projected to reach USD 1.5 billion by 2035. Public oncology infrastructure and mandatory coverage frameworks support continued treatment access despite economic constraints. Macroeconomic instability can complicate procurement and availability of imported biologics. Providers and suppliers that maintain reliable access and manage currency-sensitive operating conditions will be better positioned in this market.
Middle East & Africa Outpatient Oncology Infusion Market Analysis
Middle East & Africa is projected to reach USD 11.0 billion by 2035 and is expected to grow at approximately 11.0% CAGR (2026–2035). The outpatient oncology infusion market is supported by cancer-center investment in Gulf states and gradually expanding private-sector treatment capacity elsewhere. Regional opportunity is concentrated in markets with funded health-system modernization and specialist facilities. Outside these centers, diagnostic limitations, budget constraints, and uneven access to innovative therapy continue to restrict the pace of outpatient infusion adoption.
Saudi Arabia
Saudi Arabia generated USD 1.0 billion in 2025 and is projected to reach USD 3.0 billion by 2035. Healthcare transformation investment is supporting specialized cancer-care and ambulatory infusion capacity. New oncology centers can improve treatment access across major population centers, while national investment priorities support demand for advanced biologics. The ability to recruit specialist staff and sustain high-quality pharmacy operations will shape execution.
UAE
The UAE is projected to reach USD 2.5 billion by 2035 and is expected to grow at approximately 12.5% CAGR (2026–2035). Cancer-center development, coverage expansion, and medical tourism support its high-growth profile. The market is positioned to attract complex oncology cases through concentrated specialist capacity and private-sector investment. Maintaining reimbursement breadth for innovative therapies will be important to converting infrastructure investment into sustained infusion demand.
South Africa
South Africa generated USD 0.6 billion in 2025 and is projected to reach USD 1.5 billion by 2035. Private medical schemes and specialized oncology providers form the principal base for infused treatment growth. The private sector offers a meaningful route for adoption of advanced oncology agents, while public-sector capacity expansion remains gradual. Broader market development will depend on improvements in diagnosis, funding, and specialist-service availability.
GMI Analyst View
We expect Asia Pacific to carry the strongest strategic momentum as payer coverage, cancer-care infrastructure, and local innovation expand together. North America will remain the largest revenue base, but the center of incremental capacity investment is shifting toward Asian markets. Manufacturers will need access models that accommodate lower pricing while preserving sufficient volume and operational reach.
Outpatient Oncology Infusion Market Share & Competitive Landscape
The outpatient oncology infusion market share is moderately concentrated at the manufacturer level, with the top five companies collectively accounting for approximately 63% of supply-side revenue in 2025. Competitive advantage is concentrated around established checkpoint inhibitor franchises, antibody portfolios, ADC platforms, global distribution capabilities, and the ability to secure reimbursement across diverse outpatient settings.
Merck & Co., Inc. held approximately 19% of supply-side market share in 2025. Its position is anchored by Keytruda's broad oncology use, with the product generating USD 5.4 billion in U.S. Medicare Part B expenditures in 2023 [2]MedPAC. "July 2025 Data Book, Section 10: Prescription Drugs." medpac.gov.
Merck's strategic strength lies in the breadth of its indication coverage and the role of pembrolizumab across treatment lines and tumor types. The company's longer-term challenge is to defend this position as exclusivity dynamics evolve and competing immunotherapy and ADC programs alter oncology treatment algorithms.
Roche/Genentech held approximately 15% of supply-side market share in 2025. Its portfolio spans legacy antibodies, HER2-directed therapies, checkpoint inhibition, and ADC-related innovation.
Roche faces pricing pressure in established antibody categories where biosimilar adoption has materially changed the reference-product landscape [5]AJMC. "Samsung Bioepis Reports 2024 Biosimilar Market Growth Trends." ajmc.com. Its competitive position therefore depends increasingly on portfolio renewal, differentiated delivery formats, and the ability to convert its biologics expertise into durable positions in higher-growth treatment areas.
Bristol-Myers Squibb held approximately 12% of supply-side market share in 2025. Opdivo and the Opdivo plus Yervoy regimen provide differentiated positioning in several solid-tumor protocols.
The company's combined checkpoint blockade capability remains strategically meaningful in indications where dual-agent therapy is clinically established. Regulatory expansion in colorectal cancer further broadens the relevance of its outpatient infusion portfolio [3]U.S. Food and Drug Administration. "Oncology (Cancer)/Hematologic Malignancies Approval Notifications." fda.gov.
AstraZeneca and Johnson & Johnson (Janssen Oncology) contribute materially through distinct franchise strengths. AstraZeneca's position is supported by Imfinzi and its joint Enhertu program with Daiichi Sankyo, while Janssen benefits from the continued importance of Darzalex in multiple myeloma treatment. Darzalex generated USD 2.3 billion in U.S. Medicare Part B expenditures in 2023 [2]MedPAC. "July 2025 Data Book, Section 10: Prescription Drugs." medpac.gov.
Beyond the leading suppliers, Pfizer, Novartis, Fresenius Kabi, Hikma Pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Cipla compete through biosimilar breadth, targeted-product portfolios, and channel reach. Daiichi Sankyo, Seagen, Arcus Biosciences, G1 Therapeutics, and Turning Point Therapeutics illustrate the importance of pipeline innovation and acquisition activity in reshaping the competitive field. Competitive intensity will increasingly be determined by clinical differentiation, manufacturing reliability, reimbursement execution, and the capacity to support outpatient providers with complex drug-access requirements.
Recent Industry Developments
Enhertu Approved for HER2-Ultralow Breast Cancer, Expanding ADC-Eligible Population (January 2025)
The U.S. FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) for adults with unresectable or metastatic hormone receptor-positive, HER2-ultralow breast cancer on January 27, 2025 [7]BioPharm International. "FDA Approves AstraZeneca and Daiichi Sankyo's Enhertu for Treating HER2-low or HER2-ultralow Breast Cancer." biopharminternational.com. The AstraZeneca and Daiichi Sankyo product expands the eligible breast cancer population for HER2-directed ADC treatment and adds demand for a therapy administered through outpatient infusion.
FDA Approves Nivolumab Plus Ipilimumab for MSI-H/dMMR Colorectal Cancer (April 2025)
The FDA approved nivolumab in combination with ipilimumab for adult and pediatric patients with unresectable or metastatic MSI-H or dMMR colorectal cancer on April 8, 2025 [3]U.S. Food and Drug Administration. "Oncology (Cancer)/Hematologic Malignancies Approval Notifications." fda.gov. The approval expands the role of dual-checkpoint infusion therapy in a biomarker-defined colorectal cancer population.
Emrelis Approved as First c-Met-Directed ADC for NSCLC (May 2025)
The FDA granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for adults with locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression after prior systemic therapy on May 14, 2025 [3]U.S. Food and Drug Administration. "Oncology (Cancer)/Hematologic Malignancies Approval Notifications." fda.gov. The approval introduces a new ADC mechanism into the lung cancer outpatient infusion pathway.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →